- Home
- CATX vs SWKH Comparison
CATX vs SWKH Comparison
Compare CATX & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CATX | SWKH |
|---|---|---|
| Founded | 1983 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Diversified Financial Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.1M | 205.9M |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | CATX | SWKH |
|---|---|---|
| Price | $4.84 | $17.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | $11.78 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 7.1M | 5.5K |
| Earning Date | 03-25-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 120.89 |
| EPS | N/A | ★ 1.85 |
| Revenue | $1,075,000.00 | ★ $40,149,000.00 |
| Revenue This Year | N/A | $52.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.28 |
| Revenue Growth | N/A | ★ 62.38 |
| 52 Week Low | $1.60 | $13.17 |
| 52 Week High | $6.16 | $20.49 |
Technical Indicators
Market Signals| Indicator | CATX | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 66.96 | 44.93 |
| Support Level | $4.37 | $16.73 |
| Resistance Level | $5.00 | $17.41 |
| Average True Range (ATR) | 0.79 | 0.14 |
| MACD | 0.12 | -0.05 |
| Stochastic Oscillator | 63.47 | 56.90 |
Price Performance
Historical ComparisonAbout CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About SWKH SWK Holdings Corporation
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.